| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1036702127 |
| P356 | DOI | 10.1007/S11883-014-0472-7 |
| P698 | PubMed publication ID | 25398645 |
| P50 | author | Gerald Watts | Q71943021 |
| Jing Pang | Q51018104 | ||
| Dick Chan | Q58842465 | ||
| P2093 | author name string | Jing Pang | |
| Dick C Chan | |||
| P2860 | cites work | Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins | Q83305399 |
| Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease | Q84537980 | ||
| The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials | Q94695308 | ||
| Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans | Q73366753 | ||
| Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p | Q77829278 | ||
| Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics? | Q78030738 | ||
| Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease | Q79368237 | ||
| Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia | Q79788074 | ||
| Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy | Q80020360 | ||
| Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha | Q80175296 | ||
| Efficacy of atorvastatin therapy in ischaemic heart disease - effects on oxidized low-density lipoprotein and adiponectin | Q80793732 | ||
| The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia | Q83225668 | ||
| Pitavastatin in cardiometabolic disease: therapeutic profile | Q21246037 | ||
| Are statins diabetogenic? | Q24630205 | ||
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
| 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q28301815 | ||
| Standards of medical care in diabetes--2014 | Q28304435 | ||
| Nitric oxide induces apoptosis via Ca2+-dependent processes in the pancreatic beta-cell line MIN6 | Q28372031 | ||
| Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease | Q28373513 | ||
| The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity | Q28506782 | ||
| Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 | Q28511676 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial | Q29617817 | ||
| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials | Q29617910 | ||
| Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome | Q29619211 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials | Q29622947 | ||
| Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study | Q31829404 | ||
| Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia | Q33588898 | ||
| Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. | Q33685412 | ||
| Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia | Q33946056 | ||
| MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial | Q33966645 | ||
| Coenzyme Q10 and statins: biochemical and clinical implications | Q34003990 | ||
| Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis | Q34027392 | ||
| Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants | Q34123160 | ||
| Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients | Q34177113 | ||
| Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra | Q34189543 | ||
| ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). | Q34196167 | ||
| Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals | Q34221038 | ||
| Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion | Q34231901 | ||
| Adiponectin and Metabolic Syndrome | Q34269072 | ||
| Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial | Q34293369 | ||
| ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab | Q34368081 | ||
| Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. | Q34426322 | ||
| Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors | Q34463540 | ||
| Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus | Q34999753 | ||
| Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells | Q35028546 | ||
| Association between adiponectin concentrations and cardiovascular disease in diabetic patients: a systematic review and meta-analysis | Q35040943 | ||
| HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials | Q35065253 | ||
| Novel CoQ10 antidiabetic mechanisms underlie its positive effect: modulation of insulin and adiponectine receptors, Tyrosine kinase, PI3K, glucose transporters, sRAGE and visfatin in insulin resistant/diabetic rats | Q35106778 | ||
| Adipocytokines and insulin resistance | Q35649614 | ||
| Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'. | Q35837905 | ||
| Obesity-associated improvements in metabolic profile through expansion of adipose tissue | Q35945161 | ||
| Adiponectin increases skeletal muscle mitochondrial biogenesis by suppressing mitogen-activated protein kinase phosphatase-1. | Q35976593 | ||
| Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome | Q36148478 | ||
| Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation | Q36463044 | ||
| Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension | Q36837587 | ||
| Coenzyme Q10: is there a clinical role and a case for measurement? | Q36869671 | ||
| Risk of incident diabetes among patients treated with statins: population based study. | Q36871618 | ||
| Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. | Q36959666 | ||
| Adipokines and insulin resistance | Q36972589 | ||
| Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy. | Q37256878 | ||
| Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. | Q37362218 | ||
| Statin therapy and risk of developing type 2 diabetes: a meta-analysis | Q37364976 | ||
| Cholesterol metabolism and pancreatic beta-cell function | Q37471308 | ||
| Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis | Q37543864 | ||
| Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis | Q37632786 | ||
| Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. | Q37649260 | ||
| Role of mitochondria in beta-cell function and dysfunction. | Q37706222 | ||
| HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms | Q37838234 | ||
| Associations between single-nucleotide polymorphisms (+45T>G, +276G>T, -11377C>G, -11391G>A) of adiponectin gene and type 2 diabetes mellitus: a systematic review and meta-analysis | Q37884457 | ||
| Pitavastatin: clinical effects from the LIVES Study | Q37966067 | ||
| Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin | Q37974942 | ||
| Statins are diabetogenic--myth or reality? | Q38028072 | ||
| Is statin-induced diabetes clinically relevant? A comprehensive review of the literature | Q38174285 | ||
| The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. | Q38212766 | ||
| Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials | Q39765409 | ||
| Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study | Q40382060 | ||
| Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli | Q40382523 | ||
| Cytokines and diabetes: the final step? Involvement of TNF-alpha in both type I and II diabetes mellitus | Q40590331 | ||
| Lovastatin Disrupts Early Events in Insulin Signaling: A Potential Mechanism of Lovastatins Anti-Mitogenic Activity | Q41436012 | ||
| Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients | Q41966657 | ||
| Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control | Q42802278 | ||
| Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes | Q42813250 | ||
| Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes | Q42823990 | ||
| Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes | Q42824589 | ||
| Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice | Q42826744 | ||
| Effect of pravastatin on the development of diabetes and adiponectin production | Q42829765 | ||
| Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. | Q43289669 | ||
| Statins and risk of new-onset diabetes mellitus | Q43979349 | ||
| Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans | Q44007232 | ||
| Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. | Q44213808 | ||
| Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia | Q46198283 | ||
| Effects of antioxidants coenzyme Q10 and lipoic acid on interleukin-1 beta-mediated inhibition of glucose-stimulated insulin release from cultured mouse pancreatic islets | Q46416312 | ||
| Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia | Q46489681 | ||
| Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients | Q46533533 | ||
| Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. | Q46680003 | ||
| Effects of pitavastatin on adiponectin in patients with hyperlipidemia | Q46708651 | ||
| Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis | Q46810855 | ||
| Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. | Q50858431 | ||
| Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. | Q51373377 | ||
| Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. | Q51475159 | ||
| Integrative physiology of human adipose tissue | Q57321418 | ||
| Adiponectin and Coronary Heart Disease | Q57416324 | ||
| Direct Effect of Cholesterol on Insulin Secretion: A Novel Mechanism for Pancreatic -Cell Dysfunction | Q60642303 | ||
| P433 | issue | 1 | |
| P921 | main subject | ubidecarenone | Q321285 |
| pathogenesis | Q372016 | ||
| P304 | page(s) | 472 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Current Atherosclerosis Reports | Q20821076 |
| P1476 | title | Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10? | |
| P478 | volume | 17 |
| Q92154128 | Associations of statin use with glycaemic traits and incident type 2 diabetes |
| Q38881481 | Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes |
| Q64245365 | Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview |
| Q38586781 | Drug-Induced Hyperglycaemia and Diabetes |
| Q59791848 | Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea |
| Q91619205 | Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial |
| Q39107221 | Pitavastatin: A Review in Hypercholesterolemia |
| Q51479885 | Rosuvastatin limits the activation of hepatic stellate cells in diet-induced obese mice. |
| Q26786008 | Statin use in prediabetic patients: rationale and results to date |
| Q38553529 | Targeting inflammation in metabolic syndrome. |
| Q38669513 | The diabetogenic action of statins - mechanisms and clinical implications |
| Q41151540 | The mixed benefit of low lipoprotein(a) in type 2 diabetes. |
Search more.